The Pharmacist

MAY 21, 2024

The commitment came as part of the Welsh Government’s Strategic Workforce Plan for Primary Care for 2024/25-2029/30, published last week. The plan also committed […] The post GP pharmacists in Wales to get structured induction programme appeared first on The Pharmacist.

Pharmacy Technician 136

Pharmacy Technician 136

STAT

JUNE 25, 2024

The company said that it expects to add 1,000 new jobs, and that construction will gradually be finalized between 2027 and 2029. Novo Nordisk said the new facility would expand over 56 acres and add 1.4 million square feet of production space, doubling the combined square footage of the other three facilities in North Carolina.

248

248

Express Pharma

SEPTEMBER 24, 2023

billion by 2029, reflecting a robust 55 per cent compound annual growth rate (CAGR). billion in sales in 2029. billion in sales in 2029. billion in sales in 2029. bn in 2029: GlobalData appeared first on Express Pharma. The psychedelic drug market is on the brink of extraordinary growth, projected to soar to $7.2

Drug Development 52

Drug Development Compounding 52

Pharmaceutical Technology

FEBRUARY 8, 2024

In recognition of its 30th anniversary, the International Gaucher Alliance (IGA) unveiled a visionary five-year strategic plan extending to 2029.

52

52

STAT

SEPTEMBER 19, 2024

House committee passed a  bill  to renew a program aimed at aiding development of drugs for rare diseases in children, putting it in a better position to be added to government funding legislation , STAT reports. The pediatric rare disease priority review voucher program is set to end on Sept.

Compounding 236

Compounding Compounding Pharmacies Packaging 236

Express Pharma

JANUARY 17, 2025

GlobalData forecasts that Caplyta could generate sales of $640 million in MDD by 2029 in the 7MM. Caplyta is currently under FDA review for major depressive disorder (MDD), with a decision anticipated in the first half of 2025.

Labelling 105

Labelling 105

pharmaphorum

NOVEMBER 21, 2024

Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets

98

98

Express Pharma

MARCH 4, 2025

per cent from 2025 to 2029. The global Sugammadex market, valued at approximately 1.53 billion in 2023, is projected to grow at a CAGR of 8.5 per cent, reaching $ 2.89 billion by 2031. Overall, the pharmaceutical market in the ASEAN region is projected to grow at a CAGR of 4.83

66

66

Express Pharma

MAY 5, 2025

GlobalData projects 44 new TCI drug approvals by 2029, with 18 expected in 2027 alone. Tokali adds, CAR-T therapies are at the forefront of T-cell immunotherapy, but the entire space, including TCR-based therapies, is advancing rapidly.

65

65

Express Pharma

SEPTEMBER 4, 2023

SB5 is set to become a leading biosimilar for this debilitating, chronic condition, with a global sales forecast of $832 million by 2029, according to GlobalData. The post Humira biosimilar to see $832 million in sales by 2029: GlobalData appeared first on Express Pharma.

Biosimilars 52

Biosimilars 52

Express Pharma

APRIL 13, 2025

GlobalData estimates upadacitinib to launch in the US in 2029 and is likely to have an impact on Leqselvis patient share, as the former shares similar mechanism of action as Leqselvi. This is due to the anticipated approval and launch of another JAK inhibitor that is currently in pipeline development: AbbVies upadacitinib.

83

83

Express Pharma

SEPTEMBER 30, 2024

million by 2029, the approval of carboplatin aims to strengthen Venus Remedies’ position in the African oncology market. The authorisation of bortezomib aims to enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia. In Morocco, where the oncology drug market is set to reach $150.8

106

106

Express Pharma

JULY 10, 2024

billion in the eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and Canada) by 2029, with $375.3 million in sales in 2029. GlobalData forecasts that the ALS market will reach sales of approximately $1.3 million being contributed by 12 late-stage agents, including pridopidine.

109

109

Express Pharma

DECEMBER 3, 2023

GlobalData anticipates the drug to earn $483 million by 2029. billion by 2029. Following the news that AbbVie has agreed to buy biotech ImmunoGen , the maker of the FDA-approved ovarian cancer treatment Elahere, for $10.1 With the deal, AbbVie joins the other major pharma companies investing billions in ADC programs.

111

111

Express Pharma

FEBRUARY 21, 2024

billion by 2029. “ billion in 2023, and GlobalData projects it to surpass $14 billion by 2029. The ADC contains an anti-TROP2 monoclonal antibody covalently linked to the topoisomerase I inhibitor cytotoxic payload. GlobalData estimates the drug to earn $3.12

Chemotherapy 111

Chemotherapy Labelling Immunization Immunity 111

European Pharmaceutical Review

FEBRUARY 20, 2024

million by 2029. percent between 2022 and 2029. A report from Data Bridge Market Research has predicted that the upstream bioprocessing market will value $14,256.78 Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85

Process Improvement 98

Process Improvement Biosimilars Drug Development 98

Express Pharma

NOVEMBER 12, 2023

million cases in 2029, equating to an annual growth rate of 6.46 million cases in 2029, equating to an annual growth rate of 2.71 According to GlobalData’s Pharmaceutical Intelligence Center, the diagnosed prevalent cases of NASH in India are projected to increase from 10.7 million cases in 2023 to 12.6 million cases in 2023 to 6.5

Diabetes 106

Diabetes 106

Express Pharma

DECEMBER 28, 2023

According to GlobalData estimates, the global CGT market is projected to reach $80 billion by 2029. Oncology is expected to continue its lead as the indication and area of major development for cell and gene therapies, accounting for 44 per cent of the CGT market by 2029.

Drug Development 105

Drug Development 105

pharmaphorum

OCTOBER 4, 2021

billion in 2029 across eight major markets – the US, France, Germany, Italy, Spain, the UK, Japan, and China. It has forecast that Tecartus will reach peak sales of $110m in ALL worldwide by 2029. GlobalData predicts the ALL market will grow from $1.46 billion in 2019 to $2.26

109

109

Express Pharma

NOVEMBER 7, 2023

billion in 2022, whereas Mounjaro, which received approval in 2022, is forecast to overtake this, generating over $27 billion in 2029 alone. Cagrisema is forecast to be a blockbuster, generating nearly $8 billion in revenue in 2029. Ozempic generated global sales of $8.5

Diabetes 111

Diabetes 111

Outsourcing Pharma

JUNE 27, 2024

The US Food and Drug Administration (FDA) has approved Verona Pharmaâs Ohtuvayre (ensifentrine), marking a significant milestone in the treatment of chronic obstructive pulmonary disease (COPD).

52

52

Express Pharma

JULY 4, 2023

The latest deals will see the biotech division of the Samsung Group produce biosimilar products ranging from oncology and inflammation to immunotherapy in the period to 2029 at its new Plant 4 in South Korea. The latest orders bring this year’s combined tally of orders from Pfizer to $1.08 billion, Samsung Biologics said in a statement.

Biosimilars 105

Biosimilars 105

Pharmaceutical Technology

JULY 31, 2023

According to GlobalData, it is projected that the market for hepatitis B treatments will experience a sharp increase over the next six years.

52

52

Express Pharma

SEPTEMBER 19, 2023

billion by 2029 at a compounded annual growth rate (CAGR) of 8.2 The high prevalence of breast cancer, ovarian cancer, pancreatic cancer and cancers of the lung and intestine is a key driver of the global oncology market, which was valued at $286.04 billion in 2021 and is projected to reach $536.01 per cent from 2021 to 2030.

Chemotherapy 106

Chemotherapy Compounding 106

Pharmaceutical Technology

SEPTEMBER 22, 2023

According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.

59

59

Pharmaceutical Technology

JUNE 24, 2024

The KRAS inhibitor, Krazati, is expected to generate $1.3bn in global sales in 2029, as per GlobalData’s analysis.

Labelling 52

Labelling 52

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker.

Immunization 143

Immunization Immunity Drug Development 143

Pharmaceutical Technology

JUNE 27, 2024

Ohtuvaye is expected to rake in $1.1bn in global sales from the market for COPD patients with moderate to severe exacerbations by 2029.

52

52

European Pharmaceutical Review

JUNE 26, 2024

Completion is expected between 2027 and 2029. This is compared to the company’s $3.9 (DKK DKK 26 billion) investment in 2023, not including acquisitions. Initial construction work has begun on the new facility. Haemophilia drug could reduce treated bleeding episodes … The post New US fill finish facility receives $4.1

Diabetes 104

Diabetes Pharmaceutical Companies Pharmaceutical Companies 104

European Pharmaceutical Review

MAY 20, 2024

It is anticipated that operations will be ready to commence from 2029. The pharmaceutical firm stated that it is planning to begin the design and construction of the manufacturing facility by the end of 2024.

Chemotherapy 98

Chemotherapy 98

Pharmaceutical Technology

NOVEMBER 1, 2023

The Amgen biosimilar Wezlana has been approved for all indications and is forecasted to yield $455m in 2029.

Biosimilars 52

Biosimilars 52

PharmaTech

AUGUST 21, 2024

This Behind the Headlines news roundup panel discussion covers news items such as the resurgence of mpox in Africa, “medical tourism” in India, Eli Lilly’s new Boston CGT facilities, and contract development and manufacturing organization (CDMO) projected growth rates for the 2023–2029 period, and the reasons behind them.

52

52

Pharmaceutical Commerce

JANUARY 5, 2024

US biosimilars market projected to grow from less than $10 billion in 2022 to more than $100 billion by 2029.

Biosimilars 52

Biosimilars 52

Pharmaceutical Technology

OCTOBER 23, 2023

The Remicade biosimilar is forecasted to have sales of $2.3bn by 2029 as a subcutaneous form is approved for the US market.

Biosimilars 52

Biosimilars 52

Pharmaceutical Technology

AUGUST 31, 2023

Daiichi Sankyo and AstraZeneca’s blockbuster anti-cancer drug Enhertu could become a pan-tumour drug, with projected sales of $9.9bn by 2029.

52

52

European Pharmaceutical Review

NOVEMBER 10, 2023

The construction projects will be finalised from the end of 2025 through to 2029. Once equipped, the facility is expected to create a total of 800 jobs: 700 jobs in the new API facility and 100 jobs in the new packaging facility.

Packaging 111

Packaging Pharmaceutical Manufacturing Diabetes 111

Express Pharma

SEPTEMBER 5, 2023

billion in 2029. There are a few strategies that have been shown to lower Lp(a) levels, including niacin, Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, antisense oligonucleotides, and lifestyle modifications. GlobalData forecasts olpasiran sales to reach $1.05

106

106